U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C14H14O3
Molecular Weight 230.2592
Optical Activity UNSPECIFIED
Defined Stereocenters 1 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of NAPROXEN

SMILES

COC1=CC2=CC=C(C=C2C=C1)[C@H](C)C(O)=O

InChI

InChIKey=CMWTZPSULFXXJA-VIFPVBQESA-N
InChI=1S/C14H14O3/c1-9(14(15)16)10-3-4-12-8-13(17-2)6-5-11(12)7-10/h3-9H,1-2H3,(H,15,16)/t9-/m0/s1

HIDE SMILES / InChI

Molecular Formula C14H14O3
Molecular Weight 230.2592
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry
Defined Stereocenters 1 / 1
E/Z Centers 0
Optical Activity UNSPECIFIED

Description

Naproxen (naproxen sodium, NAPROSYN®) is a propionic acid derivative related to the arylacetic acid group of nonsteroidal anti-inflammatory drugs (NSAIDs). It is an anti-inflammatory agent with analgesic and antipyretic properties. Both the acid and its sodium salt are used in the treatment of rheumatoid arthritis and other rheumatic or musculoskeletal disorders, dysmenorrhea, and acute gout. The mechanism of action of the naproxen (naproxen sodium, NAPROSYN®), like that of other NSAIDs, is not completely understood but involves inhibition of cyclooxygenase (COX-1 and COX-2).

CNS Activity

Originator

Approval Year

PubMed

PubMed

TitleDatePubMed
Absence of pharmacokinetic interaction between orally co-administered naproxen sodium and diphenhydramine hydrochloride.
2000 Sep
Synthesis of some new 1-acylthiosemicarbazides, 1,3,4-oxadiazoles, 1,3,4-thiadiazoles and 1,2,4-triazole-3-thiones and their anti-inflammatory activities.
2001
[Two complex suicidal poisonings with drugs and their medicolegal aspects].
2001
Rofecoxib: a review of its use in the management of osteoarthritis, acute pain and rheumatoid arthritis.
2001
Differential regulation of interleukin-1 beta-induced cyclooxygenase-2 gene expression by nimesulide in human synovial fibroblasts.
2001
Nimesulide, a balanced drug for the treatment of osteoarthritis.
2001
Naproxen particle design using porous starch.
2001 Apr
Naproxen-Eudragit microspheres: screening of process and formulation variables for the preparation of extended release tablets.
2001 Apr
Reduced incidence of gastroduodenal ulcers with celecoxib, a novel cyclooxygenase-2 inhibitor, compared to naproxen in patients with arthritis.
2001 Apr
Endogenous prostaglandin E2 and insulin-like growth factor 1 can modulate the levels of parathyroid hormone receptor in human osteoarthritic osteoblasts.
2001 Apr
Celecoxib and rofecoxib. The role of COX-2 inhibitors in dental practice.
2001 Apr
Rhein, an active metabolite of diacerein, down-regulates the production of pro-matrix metalloproteinases-1, -3, -9 and -13 and up-regulates the production of tissue inhibitor of metalloproteinase-1 in cultured rabbit articular chondrocytes.
2001 Apr
Uniformly sized molecularly imprinted polymer for (S)-naproxen retention and molecular recognition properties in aqueous mobile phase.
2001 Apr 13
[Acupuncture contra antiphlogistics in acute lumbago].
2001 Apr 20
I'm taking over-the-counter ibuprofen every day for neck pain. Recently, my doctor gave me a prescription for naproxen for my arthritis. Should I be concerned about taking these two together?
2001 Aug
Localization of cyclooxygenase isozymes in cardiovascular tissues of dogs treated with naproxen.
2001 Aug 10
[Liver damage and nonsteroidal anti-inflammatory drugs: case non-case study in the French Pharmacovigilance Database].
2001 Jan-Feb
A possible mechanism of naproxen-induced lipid peroxidation in rat liver microsomes.
2001 Jul
New issues about nitric oxide and its effects on the gastrointestinal tract.
2001 Jul
Effects of non-steroidal antiinflammatory drugs and dexamethasone on the activity and expression of matrix metalloproteinase-1, matrix metalloproteinase-3 and tissue inhibitor of metalloproteinases-1 by bovine articular chondrocytes.
2001 Jul
Dapsone activation of CYP2C9-mediated metabolism: evidence for activation of multiple substrates and a two-site model.
2001 Jul
Addition of hydrogen bond donating excipients to oil solution: effect on in vitro drug release rate and viscosity.
2001 Jul
Enantioselective inhibition of the binding of rac-profens to human serum albumin induced by lithocholate.
2001 Jul
Determination of ibuprofen and naproxen in tablets.
2001 Jul
In vitro evaluation and intra-articular administration of biodegradable microspheres containing naproxen sodium.
2001 Jul-Aug
In vitro effects of NSAIDS and paracetamol on oxidative stress-related parameters of human erythrocytes.
2001 Jun
Determination of naproxen in pharmaceutical preparations by room-temperature phosphorescence. A comparative study of several organized media.
2001 Jun
By the way, doctor. Which drugs cause problems in the sun?
2001 Jun
[Treatment of pain due to unwanted lactation with a homeopathic preparation given in the immediate post-partum period].
2001 Jun
Fixed drug eruption due to naproxen; lack of cross-reactivity with other propionic acid derivatives.
2001 Jun
[The lack of awareness of the Israeli population regarding gastrointestinal complications from non-steroidal anti-inflammatory drugs].
2001 Jun
Treatment of de Quervain's disease:role of conservative management.
2001 Jun
Inhibition of tendon cell proliferation and matrix glycosaminoglycan synthesis by non-steroidal anti-inflammatory drugs in vitro.
2001 Jun
Immune thrombocytopenia resulting from sensitivity to metabolites of naproxen and acetaminophen.
2001 Jun 15
[Nitric oxide and gastroduodenal damage caused by NSAIDs. Recent findings and clinical implications].
2001 Mar
Synthesis and cyclooxygenase inhibitory properties of novel (+) 2-(6-methoxy-2-naphthyl)propanoic acid (naproxene) derivatives.
2001 Mar
Peroxisomal proliferator-activated ligand therapy for HIV lipodystrophy.
2001 Mar
Interleukin-6 (IL-6) producing phaeochromocytoma: direct IL-6 suppression by non-steroidal anti-inflammatory drugs.
2001 Mar
Effect of cyclodextrin charge on complexation of neutral and charged substrates: comparison of (SBE)7M-beta-CD to HP-beta-CD.
2001 May
Synthesis, in vitro skin permeation studies, and PLS-analysis of new naproxen derivatives.
2001 May
[The selective Cox-2 inhibition by rofecoxib reduces risk of severe gastrointestinal complications of anti-inflammatory therapy by more than 50%].
2001 May
Nimesulide reduces interleukin-1beta-induced cyclooxygenase-2 gene expression in human synovial fibroblasts.
2001 May
Severe reversible renal failure due to naproxen-associated acute interstitial nephritis.
2001 May
Effect of nonsteroidal anti-inflammatory drug use on the rate of gastrointestinal hospitalizations among people living in long-term care.
2001 May
The influence of polyvinylpyrrolidone on naproxen complexation with hydroxypropyl-beta-cyclodextrin.
2001 May
Stereoselective synthesis of (S)-(+)-Naproxen catalyzed by carboxyl esterase in a multicompartment electrolyzer.
2001 May 28
Upper gastrointestinal toxicity of rofecoxib and naproxen.
2001 May 3
Upper gastrointestinal toxicity of rofecoxib and naproxen.
2001 May 3
Isotachophoretic determination of naproxen in the presence of its metabolite in human serum.
2001 May 4
Screening procedure for detection of non-steroidal anti-inflammatory drugs and their metabolites in urine as part of a systematic toxicological analysis procedure for acidic drugs and poisons by gas chromatography-mass spectrometry after extractive methylation.
2001 May-Jun
Patents

Sample Use Guides

In Vivo Use Guide
Rheumatoid Arthritis, Osteoarthritis and Ankylosing Spondylitis: 1 tablet of NAPROSYN® (250 mg or 375 mg or 500 mg) twice daily. Acute Gout: The recommended starting dose is 750 mg of NAPROSYN® followed by 250 mg every 8 hours until the attack has subsided.
Route of Administration: Oral
In Vitro Use Guide
There are data on the N-(3-methylpyridin-2-yl)amide derivatives of flurbiprofen and naproxen (Flu-AM1 and Nap-AM1, respectively) with respect to their properties towards fatty acid amide hydrolase (FAAH). Flu-AM1 and Nap-AM1 inhibited FAAH-catalysed hydrolysis of [(3)H]anandamide by rat brain homogenates with IC50 values of 0.44 and 0.74 uM. The corresponding values for flurbiprofen and naproxen were 29 and >100 uM, respectively.
Substance Class Chemical
Created
by admin
on Mon Oct 21 22:21:57 UTC 2019
Edited
by admin
on Mon Oct 21 22:21:57 UTC 2019
Record UNII
57Y76R9ATQ
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
NAPROXEN
EP   GREEN BOOK   HSDB   INCI   INN   MART.   MI   ORANGE BOOK   USAN   USP   USP-RS   VANDF   WHO-DD  
INN   USAN   INCI  
Official Name English
NAPROXEN [USP-RS]
Common Name English
NAPROXEN [GREEN BOOK]
Common Name English
NAPROXEN [EP]
Common Name English
PN400 COMPONENT NAPROXEN
Code English
NAPROXEN [MI]
Common Name English
NAPROXEN [HSDB]
Common Name English
NAPROXEN COMPONENT OF VIMOVO
Common Name English
(+)-(S)-6-METHOXY-.ALPHA.-METHYL-2-NAPHTHALENEACETIC ACID
Systematic Name English
NAPROXEN [USP]
Common Name English
NAPROXEN [INN]
Common Name English
NAPROXEN [USAN]
Common Name English
NAPROSYN
Brand Name English
2-NAPHTHALENEACETIC ACID, 6-METHOXY-.ALPHA.-METHYL-, (S)-
Common Name English
NAPROXEN [VANDF]
Common Name English
RS-3540
Code English
VIMOVO COMPONENT NAPROXEN
Common Name English
NAPROXEN [MART.]
Common Name English
NAPROXEN [WHO-DD]
Common Name English
NAPROXEN [INCI]
Common Name English
NAPROXEN [ORANGE BOOK]
Common Name English
NAPROXEN [JAN]
Common Name English
EC-NAPROSYN
Brand Name English
Classification Tree Code System Code
NDF-RT N0000175722
Created by admin on Mon Oct 21 22:21:57 UTC 2019 , Edited by admin on Mon Oct 21 22:21:57 UTC 2019
CFR 21 CFR 522.1468
Created by admin on Mon Oct 21 22:21:57 UTC 2019 , Edited by admin on Mon Oct 21 22:21:57 UTC 2019
NDF-RT N0000175721
Created by admin on Mon Oct 21 22:21:57 UTC 2019 , Edited by admin on Mon Oct 21 22:21:57 UTC 2019
WHO-ATC G02CC02
Created by admin on Mon Oct 21 22:21:57 UTC 2019 , Edited by admin on Mon Oct 21 22:21:57 UTC 2019
WHO-VATC QM01AE56
Created by admin on Mon Oct 21 22:21:57 UTC 2019 , Edited by admin on Mon Oct 21 22:21:57 UTC 2019
WHO-VATC QM02AA12
Created by admin on Mon Oct 21 22:21:57 UTC 2019 , Edited by admin on Mon Oct 21 22:21:57 UTC 2019
NCI_THESAURUS C1323
Created by admin on Mon Oct 21 22:21:57 UTC 2019 , Edited by admin on Mon Oct 21 22:21:57 UTC 2019
WHO-VATC QG02CC02
Created by admin on Mon Oct 21 22:21:57 UTC 2019 , Edited by admin on Mon Oct 21 22:21:57 UTC 2019
LIVERTOX 668
Created by admin on Mon Oct 21 22:21:57 UTC 2019 , Edited by admin on Mon Oct 21 22:21:57 UTC 2019
WHO-VATC QM01AE52
Created by admin on Mon Oct 21 22:21:57 UTC 2019 , Edited by admin on Mon Oct 21 22:21:57 UTC 2019
WHO-ATC M01AE52
Created by admin on Mon Oct 21 22:21:57 UTC 2019 , Edited by admin on Mon Oct 21 22:21:57 UTC 2019
WHO-ATC M02AA12
Created by admin on Mon Oct 21 22:21:57 UTC 2019 , Edited by admin on Mon Oct 21 22:21:57 UTC 2019
CFR 21 CFR 520.1468
Created by admin on Mon Oct 21 22:21:57 UTC 2019 , Edited by admin on Mon Oct 21 22:21:57 UTC 2019
WHO-VATC QM01AE02
Created by admin on Mon Oct 21 22:21:57 UTC 2019 , Edited by admin on Mon Oct 21 22:21:57 UTC 2019
WHO-ATC M01AE56
Created by admin on Mon Oct 21 22:21:57 UTC 2019 , Edited by admin on Mon Oct 21 22:21:57 UTC 2019
WHO-ATC M01AE02
Created by admin on Mon Oct 21 22:21:57 UTC 2019 , Edited by admin on Mon Oct 21 22:21:57 UTC 2019
NDF-RT N0000000160
Created by admin on Mon Oct 21 22:21:57 UTC 2019 , Edited by admin on Mon Oct 21 22:21:57 UTC 2019
Code System Code Type Description
DRUG BANK
DB00788
Created by admin on Mon Oct 21 22:21:57 UTC 2019 , Edited by admin on Mon Oct 21 22:21:57 UTC 2019
PRIMARY
INN
2979
Created by admin on Mon Oct 21 22:21:57 UTC 2019 , Edited by admin on Mon Oct 21 22:21:57 UTC 2019
PRIMARY
PUBCHEM
156391
Created by admin on Mon Oct 21 22:21:57 UTC 2019 , Edited by admin on Mon Oct 21 22:21:57 UTC 2019
PRIMARY
NCI_THESAURUS
C680
Created by admin on Mon Oct 21 22:21:57 UTC 2019 , Edited by admin on Mon Oct 21 22:21:57 UTC 2019
PRIMARY
HSDB
22204-53-1
Created by admin on Mon Oct 21 22:21:57 UTC 2019 , Edited by admin on Mon Oct 21 22:21:57 UTC 2019
PRIMARY
RXCUI
7258
Created by admin on Mon Oct 21 22:21:57 UTC 2019 , Edited by admin on Mon Oct 21 22:21:57 UTC 2019
PRIMARY RxNorm
LactMed
22204-53-1
Created by admin on Mon Oct 21 22:21:57 UTC 2019 , Edited by admin on Mon Oct 21 22:21:57 UTC 2019
PRIMARY
IUPHAR
5230
Created by admin on Mon Oct 21 22:21:57 UTC 2019 , Edited by admin on Mon Oct 21 22:21:57 UTC 2019
PRIMARY
MESH
D009288
Created by admin on Mon Oct 21 22:21:57 UTC 2019 , Edited by admin on Mon Oct 21 22:21:57 UTC 2019
PRIMARY
ChEMBL
CHEMBL154
Created by admin on Mon Oct 21 22:21:57 UTC 2019 , Edited by admin on Mon Oct 21 22:21:57 UTC 2019
PRIMARY
MERCK INDEX
M7769
Created by admin on Mon Oct 21 22:21:57 UTC 2019 , Edited by admin on Mon Oct 21 22:21:57 UTC 2019
PRIMARY Merck Index
CAS
22204-53-1
Created by admin on Mon Oct 21 22:21:57 UTC 2019 , Edited by admin on Mon Oct 21 22:21:57 UTC 2019
PRIMARY
EVMPD
SUB09159MIG
Created by admin on Mon Oct 21 22:21:57 UTC 2019 , Edited by admin on Mon Oct 21 22:21:57 UTC 2019
PRIMARY
EPA CompTox
22204-53-1
Created by admin on Mon Oct 21 22:21:57 UTC 2019 , Edited by admin on Mon Oct 21 22:21:57 UTC 2019
PRIMARY
WIKIPEDIA
NAPROXEN
Created by admin on Mon Oct 21 22:21:57 UTC 2019 , Edited by admin on Mon Oct 21 22:21:57 UTC 2019
PRIMARY
ECHA (EC/EINECS)
244-838-7
Created by admin on Mon Oct 21 22:21:57 UTC 2019 , Edited by admin on Mon Oct 21 22:21:57 UTC 2019
PRIMARY
Related Record Type Details
SALT/SOLVATE -> PARENT
BINDER->LIGAND
BINDING
BASIS OF STRENGTH->SUBSTANCE
ASSAY (TITRATION)
EP
METABOLIC ENZYME -> SUBSTRATE
SALT/SOLVATE -> PARENT
METABOLIC ENZYME -> SUBSTRATE
BASIS OF STRENGTH->SUBSTANCE
ASSAY (TITRATION)
USP
TRANSPORTER -> INHIBITOR
SALT/SOLVATE -> PARENT
METABOLIC ENZYME -> SUBSTRATE
SALT/SOLVATE -> PARENT
TRANSPORTER -> INHIBITOR
TRANSPORTER -> INHIBITOR
TRANSPORTER -> INHIBITOR
Related Record Type Details
METABOLITE INACTIVE -> PARENT
Naproxen is extensively metabolized to 6-0-desmethyl naproxen and both parent and metabolites do not induce metabolizing enzymes
METABOLITE INACTIVE -> PARENT
METABOLITE INACTIVE -> PARENT
METABOLITE INACTIVE -> PARENT
Related Record Type Details
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
UNSPECIFIED
EP
IMPURITY -> PARENT
UNSPECIFIED
EP
IMPURITY -> PARENT
UNSPECIFIED
EP
IMPURITY -> PARENT
UNSPECIFIED
EP
IMPURITY -> PARENT
UNSPECIFIED
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
UNSPECIFIED
EP
IMPURITY -> PARENT
UNSPECIFIED
EP
IMPURITY -> PARENT
UNSPECIFIED
EP
IMPURITY -> PARENT
UNSPECIFIED
EP
IMPURITY -> PARENT
UNSPECIFIED
EP
IMPURITY -> PARENT
UNSPECIFIED
EP
IMPURITY -> PARENT
For the calculation of contents, multiply the peak areas by 2.0
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
UNSPECIFIED
EP
Related Record Type Details
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
EXCRETION PHARMACOKINETIC
Volume of Distribution PHARMACOKINETIC
ORAL BIOAVAILABILITY PHARMACOKINETIC
MAXIMUM TOLERATED DOSE TOXICITY
Tmax PHARMACOKINETIC FOOD EFFECT
PHARMACOKINETIC
Tmax PHARMACOKINETIC
Tmax PHARMACOKINETIC
Biological Half-life PHARMACOKINETIC